In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice

Kishida, Tsunao; Asada, Hidetsugu; Satoh, Etsuko; Tanaka, Saiyu; Shin‐Ya, Masaharu; Hirai, Hideyo; Iwai, Masaki; Tahara, Hideaki; Imanishi, Jirô; Mazda, Osam

doi:10.1038/sj.gt.3301519

Cited by 95 publications

(77 citation statements)

References 54 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…51 Luciferase activity was examined on day 7 as described previously. 14 To assess growth rate of tumors, the diameters of PC tumors were scaled with a digital scalper and their volumes were calculated as follows: tumor volume¼a Â b 2 /2 (mm 3 ), where a is the long diameter and b the short diameter.…”

Section: In Vivo Transfection Into Pc Tumorsmentioning

confidence: 99%

Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo

et al. 2003

Self Cite

View full text Add to dashboard Cite

Section: In Vivo Transfection Into Pc Tumorsmentioning

confidence: 99%

Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo

et al. 2003

Self Cite

View full text Add to dashboard Cite

“…Applications of this technique have been extended from treating muscular dystrophy to using muscle for systemic delivery of therapeutic proteins. [97][98][99][100][101] The mechanisms by which this method enhances transgene expression appear to be relatively simple. Electroporation is effective only when plasmid DNA is injected into the muscle prior to, not after, electroporation.…”

Section: Electroporationmentioning

confidence: 99%

Non-viral gene delivery in skeletal muscle: a protein factory

Lu¹,

Bou‐Gharios²,

Partridge³

2003

Gene Ther

168

109

View full text Add to dashboard Cite

Ever since the publication of the first reports in 1990 using skeletal muscle as a direct target for expressing foreign transgenes, an avalanche of papers has identified a variety of proteins that can be synthesized and correctly processed by skeletal muscle. The impetus to the development of such applications is not only amelioration of muscle diseases, but also a range of therapeutic applications, from immunization to delivery of therapeutic proteins, such as clotting factors and hormones. Although the most efficient way of introducing transgenes into muscle fibres has been by a variety of recombinant viral vectors, there are potential benefits in the use of non-viral vectors. In this review we assess the recent advances in construction and delivery of naked plasmid DNA to skeletal muscle and highlight the options available for further improvements to raise efficiency to therapeutic levels.

show abstract

“…pGEG.luc harbors a firefly luciferase gene as described (Figure 1, lower panel). 55 Plasmids were purified using Qiagen Maxiprep Endofree kits (Qiagen, Hilden, Germany).…”

Section: Plasmid Vectorsmentioning

confidence: 99%

“…Specific 51 Cr release was calculated according to the standard formula. 55 ELISA Sera were obtained from the carotid artery of mice 3 days after the last immunization. Cytokine concentrations in the sera were assayed using mouse IL-12 (BioSource International, Camarillo, CA, USA) and IFN-g (BioSource International, Camarillo, CA, USA) ELISA kits according to the supplier's instructions.…”

Section: Cytotoxicity Assaysmentioning

confidence: 99%

Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice

Asada

Kishida

et al. 2003

Gene Ther

Self Cite

View full text Add to dashboard Cite

Naked plasmid DNA (pDNA) vaccine expressing herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) was tested for protective activity against acute HSV-1 infection in mice. The pDNA was intravenously injected into Balb/c mice via their tail vein under high pressure, and the vaccination was performed two times at an interval of 7 days. The gB gene vaccination significantly protected the mice from subsequent intraperitoneal challenge with a lethal dose of HSV-1, which killed all the animals given control plasmid or saline. The protective activity was correlated with the dose of the plasmid inoculated, the survival rate reaching 83% in mice vaccinated with 5 mg of pDNA. The vaccinated mice were also protected from latent HSV infection. The immunized mice showed significant elevation in neutralizing antibody against HSV-1 as well as serum levels of interleukin-12 (IL-12) and interferon-g (IFN-g). When mice were immunized with 5 mg of an Epstein-Barr virus (EBV)-based plasmid vector harboring the gB, the cytotoxic T lymphocytes (CTLs) activity and proliferative response for HSV-1 were also induced. The results strongly suggest that intravenous immunization of naked pDNA may induce humoral and cellular immune responses against the virus, leading to a significant prophylactic outcome against HSV-1 infection in mice.

show abstract

In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice

Abstract: Direct intratumoral transfection of cytokine genes was per-

Cited by 95 publications

References 54 publications

Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo

Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo

Non-viral gene delivery in skeletal muscle: a protein factory

Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice

Contact Info

Product

Resources

About